437P Risk factors for trastuzumab-deruxtecan–related interstitial lung disease: A multicenter competing risk analysis

Key Points

• This research aims to identify risk factors for interstitial lung disease related to trastuzumab-deruxtecan in patients.
• Conducted a multicenter analysis to evaluate contributing factors for interstitial lung disease.
• Analyzed imaging biomarkers associated with trastuzumab-deruxtecan treatment.
• Utilized data from clinical trial NCT04125277.
• Identified significant imaging biomarkers linked to interstitial lung disease rates.
• Risk factors vary across different patient demographics and treatment histories.